✦ LIBER ✦

33 INVITED Combination of tyrosine kinase inhibitors, or monoclonal antibodies, with radiotherapy and chemotherapy

✍ Scribed by M.J. Ratain

Book ID: 118623662
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 274 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70039-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

30 INVITED Combination of monoclonal ant

30 INVITED Combination of monoclonal antibodies and Tyrosine Kinase Inhibitors with the same target

✍ J. Baselga 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Improved Effect of an Antiangiogenic Tyr

Improved Effect of an Antiangiogenic Tyrosine Kinase Inhibitor (SU5416) by Combinations with Fractionated Radiotherapy or Low Molecular Weight Heparin

✍ Lund, Eva L.; Olsen, Minna W.B.; Lipson, Kenneth E.; McMahon, Gerald; Howlett, A 📂 Article 📅 2003 🏛 Neoplasia Press 🌐 English ⚖ 139 KB

36 Improved Inhibition of Tumor Growth b

36 Improved Inhibition of Tumor Growth by the Novel Monoclonal Antibody VGX-100 Targeting VEGF-C in Combination with VEGF-Receptor Tyrosine Kinase Inhibitors

✍ Tester, A.; Phelan, D.; Gerometta, M.; Klupacs, R.; Baldwin, M.E. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Anti-tumor activity of the combination o

Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

✍ Maria Pia Morelli; Tina Cascone; Teresa Troiani; Concetta Tuccillo; Roberto Bian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB

## Abstract Purpose: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth. Vascular endothelial growth factor A (VEGF‐A) is a key regulator of tumor‐induced endothelial cell proliferation and vascular permeability. ZD6474 is an orally available

90 POSTER Differential effects of blocka

90 POSTER Differential effects of blockade of the HER3-PI3K-Akt pathway by EGFR kinase inhibitors and EGFR monoclonal antibodies on combinations with IGF-1R kinase inhibition

✍ E. Buck; A. Eyzaguirre; D. Epstein; J. Pachter; J. Haley; N. Miglarese; K. Iwata 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Dose scheduling of the dual VEGFR and EG

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

✍ Daniel L. Gustafson; Barbara Frederick; Andrea L. Merz; David Raben 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 481 KB